Literature DB >> 11145959

Different usage of the glycosaminoglycan attachment sites of biglycan.

H Kresse1, D G Seidler, M Muller, E Breuer, H Hausser, P J Roughley, E Schonherr.   

Abstract

Biglycan is a member of the small leucine-rich proteoglycan family. Its core protein comprises two chondroitin/dermatan sulfate attachment sites on serine 42 and serine 47, respectively, which are the fifth and tenth amino acid residues, respectively, after removal of the prepro peptide. Because the regulation of glycosaminoglycan chain assembly is not fully understood and because of the in vivo existence of monoglycanated biglycan, mutant core proteins were stably expressed in human 293 and Chinese hamster ovary cells in which i) either one or both serine residues were converted into alanine or threonine residues, ii) the number of acidic amino acids N-terminal of the respective serine residues was altered, and iii) a hexapeptide was inserted between the mutated site 1 and the unaltered site 2. Labeling experiments with [(35)S]sulfate and [(35)S]methionine indicated that serine 42 was almost fully used as the glycosaminoglycan attachment site regardless of whether site 2 was available or not for chain assembly. In contrast, substitution of site 2 was greatly influenced by the presence or absence of serine 42, although additional mutations demonstrated a direct influence of the amino acid sequence between the two sites. When site 2 was not substituted with a glycosaminoglycan chain, there was also no assembly of the linkage region. These results indicate that xylosyltransferase is the rate-limiting enzyme in glycosaminoglycan chain assembly and implicate a cooperative effect on the xylosyl transfer to site 2 by xylosylation of site 1, which probably becomes manifest before the removal of the propeptide. It is shown additionally that biglycan expressed in 293 cells may still contain the propeptide sequence and may carry heparan sulfate chains as well as sulfated N-linked oligosaccharides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145959     DOI: 10.1074/jbc.M009321200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Excess biglycan causes eyelid malformation by perturbing muscle development and TGF-alpha signaling.

Authors:  Yasuhito Hayashi; Chia-Yang Liu; James J Jester; Miyuki Hayashi; I-Jong Wang; James L Funderburgh; Shizuya Saika; Peter J Roughley; Candace Whei-Cheng Kao; Winston Whei-Yang Kao
Journal:  Dev Biol       Date:  2005-01-01       Impact factor: 3.582

2.  The chondroitin sulfate form of invariant chain trimerizes with conventional invariant chain and these complexes are rapidly transported from the trans-Golgi network to the cell surface.

Authors:  Lynne S Arneson; Jim Miller
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

3.  Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype.

Authors:  Ariane Melchior-Becker; Guang Dai; Zhaoping Ding; Liliana Schäfer; Jürgen Schrader; Marian F Young; Jens W Fischer
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

4.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages.

Authors:  Liliana Schaefer; Andrea Babelova; Eva Kiss; Heinz-J Hausser; Martina Baliova; Miroslava Krzyzankova; Gunther Marsche; Marian F Young; Daniel Mihalik; Martin Götte; Ernst Malle; Roland M Schaefer; Hermann-Josef Gröne
Journal:  J Clin Invest       Date:  2005-07-14       Impact factor: 14.808

5.  The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis.

Authors:  Zoran V Popovic; Shijun Wang; Maria Papatriantafyllou; Ziya Kaya; Stefan Porubsky; Maria Meisner; Mahnaz Bonrouhi; Sven Burgdorf; Marian F Young; Liliana Schaefer; Hermann-Josef Gröne
Journal:  J Immunol       Date:  2011-11-16       Impact factor: 5.422

6.  Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlers-Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I (beta4GalT-7).

Authors:  Daniela G Seidler; Muhammad Faiyaz-Ul-Haque; Uwe Hansen; George W Yip; Syed H E Zaidi; Ahmad S Teebi; Ludwig Kiesel; Martin Götte
Journal:  J Mol Med (Berl)       Date:  2006-04-01       Impact factor: 4.599

7.  Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors.

Authors:  Andrea Babelova; Kristin Moreth; Wasiliki Tsalastra-Greul; Jinyang Zeng-Brouwers; Oliver Eickelberg; Marian F Young; Peter Bruckner; Josef Pfeilschifter; Roland M Schaefer; Hermann-Josef Gröne; Liliana Schaefer
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

8.  Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury.

Authors:  Liliana Schaefer; Daniel Mihalik; Andrea Babelova; Miroslava Krzyzankova; Hermann-Josef Gröne; Renato V Iozzo; Marian F Young; Daniela G Seidler; Guoqing Lin; Dieter P Reinhardt; Roland M Schaefer
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 9.  The bladder extracellular matrix. Part I: architecture, development and disease.

Authors:  Karen J Aitken; Darius J Bägli
Journal:  Nat Rev Urol       Date:  2009-11       Impact factor: 14.432

10.  Effects of modifiers of glycosaminoglycan biosynthesis on outflow facility in perfusion culture.

Authors:  Kate E Keller; John M Bradley; Mary J Kelley; Ted S Acott
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.